Focused Ultrasound Foundation: Pre-Clinical and Clinical Research Awards (multiple opportunities)

The Foundation strives to create knowledge by funding research to accelerate the field of focused ultrasound toward the clinic and to improve patient care. Our funding supports investigators in academia and medical research disciplines around the globe and projects across various stages of research. Our Pre-Clinical Awards support early, proof-of-concept projects and animal studies aimed at either developing new therapeutic mechanisms or demonstrating pre-clinical safety or efficacy in specific disease areas. Our Clinical Trial Awards provide funding for first-in-human and other innovative clinical trials. In order to obtain funding, the proposed research must involve or advance the use of minimally or non-invasive image-guided focused ultrasound.

Clinical Awards
The Foundation funds first-in-human and other innovative clinical trials involving the use of image-guided focused ultrasound to treat diseases. Funding for clinical trials is determined through a peer-review process, and the timing and dollar amounts are determined on a case-by-case basis. Priority is given to clinical indications with a clear patient need. Application instructions and materials are provided here.

Pre-Clinical Awards
The Foundation provides funding for investigator-initiated pre-clinical or early-stage research projects through a competitive peer-reviewed application process. Applying for pre-clinical research funding is covered here.

Our Pre-Clinical Awards Program support investigator-initiated research projects in the form of one-year awards totaling approximately $100,000, paid out in three or more installments tied to progress reports throughout the term of the project. This program typically does not fund large capital purchases, overhead or institutional expenses, and the development of new focused ultrasound equipment. Exceptions to these guiding principles may be considered if the project addresses a gating factor in the near-term development of a reimbursable clinical application. Robust scientific design is prioritized over positive results (high failure risk is acceptable), and translational projects are preferred.